Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Intelsius Enhances Patient Safety Products

Published: Thursday, February 13, 2014
Last Updated: Wednesday, February 12, 2014
Bookmark and Share
Company announces enhancement to ThermoTrek™ range of solutions.

Intelsius has announced an enhancement to its ThermoTrek™ range of solutions. They now feature ThermoCline Technology™ (TCT) allowing 48 plus hours of protection for temperature sensitive payloads. The TCT addition allows for simple conditioning of a single component making it easy for patients to use correctly.

ThermoTrek systems are a range of insulated, patient carry cases designed for movement of temperature sensitive medications (2-8 degrees C) either being tested in clinical trials or for approved and marketed medicines used by patients.

“Pharmaceutical companies make enormous investments in their IMPs during clinical trials and the ThermoTrek TCT systems will help patients comply with temperature sensitivity requirements and provide more reliable clinical data outcomes,” said Steve Healy, Intelsius Global Sales Director.

In commercially available temperature sensitive medicines, the system protects the patient’s investment in treatment while ensuring efficacy of the medicine.

The optional Thermochromic label on the TCT panel visually indicates and verifies the readiness for use.

“Keeping patients safe is the primary reason for the ThermoTrek TCT line of products and simplified conditioning makes it extremely easy for them to use,” said Healy. “In addition, we’ve already had great feedback from leading Pharma companies who are shipping high value biologics direct to pharmacies here in Europe.”

Every ThermoTrek TCT solution is constructed with high performance materials which give a strong resistance to tears or abrasions while offering stain and water resistance for many months of reliable use.

Each case is ergonomically designed to have a minimum impact on the patient’s daily life and enable comfortable transportation of medicine. In addition, its discreet design keeps the contents confidential.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!